Proportion of Brazilian diabetes patients that achieve treatment goals: implications for better quality of care by Deise Regina Baptista et al.
Baptista et al. Diabetol Metab Syndr  (2015) 7:113 
DOI 10.1186/s13098-015-0107-3
RESEARCH
Proportion of Brazilian diabetes patients 
that achieve treatment goals: implications 
for better quality of care
Deise Regina Baptista1*, Rubia Daniela Thieme2, Walleri Christini Torelli Reis3, Roberto Pontarolo3 
and Cassyano Januário Correr3
Abstract 
Background: Diabetes and its complications are substantial causes of morbidity and mortality, and caused approxi-
mately 5.1 million deaths worldwide in 2013. Early detection and treatment of diabetes complications can prevent 
their progression.
Object: This study compared the proportions of patients with type 1 and 2 diabetes mellitus (T1DM and T2DM, 
respectively) who achieved the goals of good clinical control.
Methods: Adults and elderly patients with T1DM and T2DM at a public outpatient endocrinology service in Brazil 
were retrospectively evaluated between 2012 and 2013. Clinical and socio demographic data were obtained from 
medical records and evaluated in accordance with the Brazilian Diabetes Society Guidelines. Care process measures, 
outcomes indicators, and supporting process measures were evaluated.
Results: A total of 1031 records were analyzed: 29 and 71 % of patients had T1DM and T2DM, respectively. T2DM 
patients had significantly higher BMI than T1DM patients (overweight and obesity in 85.1 vs. 47.5 %, p < 0.01). The 
follow-up periods for diabetes and number of clinical visits to the endocrinology service were significantly greater 
among T1DM patients than T2DM patients (p < 0.01). However, T2DM patients required significantly more other (i.e., 
non-endocrinological) healthcare services (p < 0.01). HbA1c was significantly lower in T2DM patients (p < 0.01). More-
over, blood pressure and triglycerides were significantly higher in T2DM patients (p < 0.01), whereas total cholesterol 
and low-density lipoprotein were significantly lower in T2DM patients (p < 0.01). Only 0.5 % of the patients achieved 
all targets, and 1.1 % did not achieve any.
Conclusions: The achievement of goals of good clinical practice varies among the parameters evaluated. Almost 
no patients achieved all targets. Many patients are overweight and do not achieve targets for HbA1c, lipid profile, or 
blood pressure control.
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Background
The number of diabetes cases has increased over the 
last few decades, representing a global epidemic. In 
2013, an estimated 382 million people had diabetes, 
which is projected to increase to 592 million by 2035 
[1]. This problem is particularly important when taking 
into account the clinical, humanitarian, and economic 
impacts of the condition [2–5]. In the United States of 
America, diabetes accounts for almost 14 % of healthcare 
expenditures [6]. Moreover, diabetes is associated with a 
high prevalence of depression [7] and adversely impacts 
employment, absenteeism, and work productivity [4].
The disease is classified as type 1 diabetes mellitus 
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diabetes mellitus (T2DM), accounting for 90–95  % of 
cases. The cause of T1DM, which often develops dur-
ing childhood and adolescence, is absolute deficiency of 
insulin secretion due to a cellular-mediated autoimmune 
or idiopathic destruction of pancreatic β-cells. Mean-
while, T2DM is characterized by variable degrees of insu-
lin deficiency and resistance, and is commonly present in 
obese adults and the elderly [1, 8, 9].
Defective insulin secretion and/or action results in 
hyperglycemia, which is associated with long-term com-
plications, dysfunction, and failure including retinopathy, 
nephropathy, peripheral neuropathy with a risk of foot 
ulcers, lower-limb amputations, Charcot joints, auto-
nomic neuropathy, sexual dysfunction, cardiovascular 
disease, hypertension, and lipoprotein abnormalities [9]. 
Diabetes and its complications are substantial causes of 
morbidity and mortality, and caused approximately 5.1 
million deaths worldwide in 2013 [1, 8].
Early detection and treatment of diabetes complications 
can prevent their progression. Eye examinations, urine 
tests, foot examinations, blood lipid and glucose control, 
blood pressure and lipid management, medication adher-
ence, smoking cessation, healthy diet, regular physical 
activity, and maintaining normal body weight are recom-
mended actions. Health outcomes are better when diabetes 
patients are treated in the context of organized programs 
with coordinated teams of health professionals [10, 11].
The Support Network for diabetes established by the 
National Brazilian Health Care System (NBHCS) aims to 
improve the quality of care for patients with diabetes on 
the basis of integrality, longitudinality, and health educa-
tion; ultimately, the program aims to increase treatment 
efficiency, self-care, and quality of life in an attempt to 
achieve the goals recommended by guidelines issued by 
diabetes societies to control cardiovascular risk factors 
and chronic complications [12, 13]. However, there is a 
discrepancy between the goals recommended in these 
guidelines and the values instilled into the patients as 
well as the frequency of screening for chronic complica-
tions; therefore, the quality of care for diabetes patients 
must be improved [14].
Considering the lack of studies comparing the effective-
ness of healthcare for patients with T1DM and T2DM, 
the present study compared the proportions of patients 
with T1DM and T2DM who achieved the goals of good 
clinical practice during routine secondary endocrine care 
at the NBHCS Support Network.
Methods
This retrospective cohort study was conducted between 
January 2012 and December 2013 in a public outpatient 
clinic at a university hospital in Curitiba, Paraná, Brazil. 
Adults older than 18 years and elderly people older than 
60 years [15] with T1DM and T2DM routinely attending 
this outpatient endocrinology service were included. This 
study meets the standards of research in humans and was 
approved by the Ethics Committee of the Universidade 
Federal do Paraná, Hospital de Clínicas (#411.484).
Data were obtained from the latest medical records 
from clinical and physical examinations performed by a 
physician. Information was limited to medical records 
involving at least one medical consultation at the outpa-
tient endocrinology service, specifically within the last 6 
months. Data were collected on the basis of the goals for 
adequate metabolic control and management of diabetes 
recommended by the Brazilian Diabetes Society (BDS) 
Guidelines [16]. The following variables were assessed: 
age, sex, period of treatment for diabetes (years), weight 
(kg), height (cm), body mass index (BMI, kg/m2), pro-
cess measurements, outcomes indicators, and supporting 
process measurements (not required by the BDS).
Process measurements included the frequency of 
patients who underwent evaluation of the following 
parameters at least once in the last 6 months: systolic 
and diastolic blood pressure (sBP and dBP, respectively, 
mmHg), glycated hemoglobin (HbA1c) (%), total cho-
lesterol (TC), low-density lipoprotein (LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol, triglycerides 
(TG), abdominal circumference, education for smoking 
cessation, angiotensin-converting enzyme (ACE) inhibi-
tor or angiotensin II receptor antagonist (ARA2), and 
aspirin prescription; parameters evaluated in the last year 
were funduscopy and microalbuminuria upon request, 
and foot examination.
The outcome indicators were the latest sBP and dBP, 
HbA1c, TC, LDL, HDL, and TG values in the medical 
records as well as nutritional education, physical educa-
tion, glucose self-monitoring, and patient satisfaction 
with the service. BMI was considered an indicator of 
metabolic control. The BDS (2012–2013) recommends 
the following targets for the metabolic control of diabetes 
patients:
1. HbA1c above the upper limit of the normal range, 
i.e., ≤7.0 % (53 mmol/mol), keeping in mind the goal 
can be individualized to the patient
2. sBP  <130  mmHg for adults and  <150  mmHg for 
elderly patients




6. HDL cholesterol >1.2 mmol/L for men and women
7. LDL cholesterol <2.6 mmol/L for adults without car-
diovascular disease
8. Triglycerides <1.7 mmol/L.
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Supporting process measurement indicators included 
treatments for diabetes (i.e., diet, oral hypoglycemic 
agent [OHA] monotherapy, OHA combination therapy, 
insulin monotherapy, and insulin plus OHA combination 
therapy), antihyperlipidemic agents, antihypertensive 
agents, and number of clinical visits (i.e., endocrinology 
service for diabetes care and others) in the last year. All 
health procedures and laboratory exams followed the 
same methodological protocol established in the hospital.
Statistical analyses were performed using SPSS for 
Windows version 20.0 (SPSS Inc., Chicago, IL, USA). For 
descriptive statistics, the normality and homoscedasticity 
of the distribution of all parameters were determined by 
the Kolmogorov–Smirnov test. Frequencies were accord-
ingly expressed as means and standard deviations (SD) 
or medians and ranges where appropriate. The variation 
in sample distribution and mean differences were per-
formed using the Mann–Whitney test.
The variables studied, were submitted to bivariate 
inferential analysis according to their clinical coherence 
by using the parametric Pearson test and nonparametric 
of Spearman test. Proportions were compared using the 
χ2 test or Fisher’s exact test where appropriate. The level 
of statistical significance was set at p < 0.05.
Results
Data from a total of 1031 medical records were analyzed: 
there were 299 (29 %) T1DM patients (55.2 % female) and 
732 (71 %) T2DM patients (68.0 % female). T2DM patients 
were significantly older than T1DM patients (p  <  0.01). 
All patients received healthcare from the NBHCS at the 
same outpatient endocrinology service for diabetes care. 
No medical records contained information about patient 
satisfaction with their diabetes care. The treatment period 
for diabetes and number of clinical visits to the endocri-
nology service were greater in T1DM than T2DM patients 
(p < 0.01). However, T2DM patients required more “other” 
healthcare than T1DM patients (p < 0.01) (Table 1).
The proportions of T1DM and T2DM patients who 
reached the goals for BMI differed significantly (Table 5). 
BMI was significantly higher in T2DM patients than 
T1DM patients (p < 0.01) (Table 1): 47.5 % (n = 142) of 
T1DM patients were overweight or obese compared to 
85.1 % (n = 605) of T2DM patients (p = 0.001). Abdomi-
nal circumference was rarely measured in both T1DM 
and T2DM patients (1.7  % and 1.1  %, respectively). 
Regarding smoking status, 14 % (n =  42) of T1DM and 
17.9  % (n =  131) of T2DM patients had data available; 
accordingly, 6.2 % (n = 23) and 5.6 % (n = 41) of T1DM 
and T2DM patients were smokers, respectively.
Most patients achieved metabolic control according 
to blood examination as a process measure in the last 
6  months (93.69–99.42  %). The median values differed 
significantly between T1DM and T2DM patients: sBP, 
dBP, and TG were significantly higher in patients with 
T2DM (p < 0.01), whereas TC and LDL were significantly 
lower in patients with T2DM (p  <  0.01). Furthermore, 
HDL was significantly higher in T1DM patients (p < 0.01) 
(Table  2). T1DM patients received fewer prescriptions 
for antihyperlipidemic agents, antihypertensive agents, 
and aspirin (p < 0.01) (Tables 3, 4).
T2DM patients underwent foot and eye exami-
nations significantly less frequently than patients 
with T1DM (p  <  0.01). However, the frequency of 
urine albumin screening was similar between groups 
(p > 0.05). Information regarding nutritional education 
was present in 44  % of the medical records (Table  3), 
but 98  % of the patients (n  =  1008) did not receive 
nutritional consultation. Furthermore, physical edu-
cation and mainly, education for smoking cessation 
were neglected by physicians in medical records as 
reflected by the low frequency of registration. Educa-
tion for smoking cessation was similar between T1DM 
and T2DM patients (p > 0.05), whereas T2DM patients 
received physical and nutritional education signifi-
cantly more frequently than T1DM patients (p < 0.01). 
Table 1 Characteristics of type 1 and 2 diabetes mellitus patients
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, BMI body mass index
* Mann–Whitney U test
a Median (range)
n T1DM + T2DMa n T1DMa n T2DMa p value*
Age (years) 1030 57.0 (18–92) 298 31.0 (18–70) 732 62.0 (22–92) <0.01
Weight (kg) 1015 74.0 (27.0–139.0) 281 66.3 (27.0–128.5) 706 77.4 (38.8–139.0) <0.01
Height (cm) 988 160.0 (139.0–196.0) 281 164.0 (140.0–196.0) 706 1.59 (139.0–187.0) <0.01
BMI (kg/m2) 987 28.1 (11.8–54.3) 281 24.3 (11.8–46,1) 706 29.8 (17.7–54.3) <0.01
Number of clinical visits—DM (last year) 1030 2.0 (0–11) 298 3.0 (0–5) 732 2.0 (0–11) <0.01
Number of clinical visit—other (last year) 1031 1.0 (0–57) 299 0.0 (0–37) 732 1.0 (0–57) <0.01
Period of treatment for DM (years) 1027 7.0 (0–30.0) 297 9.0 (0–30.0) 730 6.0 (0–30.0) <0.01
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Significantly more T1DM patients performed glu-
cose self-monitoring than T2DM patients (p  <  0.01) 
(Table 3).
HbA1c level was significantly lower in T2DM patients 
than T1DM patients (p  <  0.01) (Table  2). Insulin plus 
OHA combination therapy and insulin monotherapy 
were the most frequently prescribed treatments. Insulin 
monotherapy was prescribed for 86 % of T1DM patients, 
and insulin plus OHA combination therapy was pre-
scribed for 47 % of T2DM patients (Table 4).
Table 2 Process measurements and outcome measures of patients with type 1 and 2 diabetes mellitus
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, dBP diastolic blood pressure, TC total cholesterol, HDL high-density lipoprotein cholesterol, LDL low-
density lipoprotein cholesterol, TG triglycerides, sBP systolic blood pressure
* Mann–Whitney U test
a Median (range)
n T1DM + T2DMa n T1DMa n T2DMa p value*
sBP (mmHg) 1025 120 (70–222) 296 120 (70–222) 729 130 (80–220) 0.00
dBP (mmHg) 1025 80 (40–130) 296 70 (40–121) 729 80 (51–130) 0.01
HbA1c (%) 1004 8.2 (4.1–16.2) 299 9.0 (4.1–16.2) 711 7.8 (4.3–16.0) 0.00
TC (mmol/L) 984 4.3 (1.9–9.1) 287 4.4 (2.6–8.3) 697 4.3 (1.9–9.1) 0.01
HDL (mmol/L) 986 1.1 (0.4–2.5) 288 1.2 (0.5–2.5) 698 1.0 (0.4–1.5) 0.00
LDL (mmol/L) 966 2.5 (0.4–6.8) 281 2.6 (1.0–6.7) 685 2.4 (0.4–6.8) 0.00
TG (mmol/L) 984 1.3 (0.2–9.3) 288 1.0 (0.3–7.9) 695 1.5 (0.2–9.3) 0.00
Table 3 Frequencies of  requests, prescriptions, and  educational actions as  process measures and  outcomes indicators 
for patients with type 1 and 2 diabetes mellitus
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, ACE angiotensin-converting enzyme
* χ2 test
** Fisher’s exact test
n T1DM + T2DM (%) n T1DM (%) n T2DM (%) p value
Foot examination 618 59.9 227 75.9 391 53.4 0.00*
Funduscopy 445 43.2 164 54.8 451 38.4 0.00*
Microalbuminuria 942 91.4 266 89.0 676 92.3 0,08*
Nutritional education 457 44.3 109 36.5 348 47.5 0.00*
Physical education 266 25.8 60 20.1 206 28.1 0.00*
Smoking cessation education 14 1.4 4 1.3 10 1.4 1.00**
Glucose self-monitoring 637 61.8 247 82.6 390 53.3 0.00*
ACE or ARA2 inhibitor prescription 677 65.66 123 41.13 554 75.7 0.00**
Aspirin prescription 525 50.9 60 20.1 465 63.5 0.00*
Table 4 Supporting process measures of patients with type 1 and 2 diabetes mellitus
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, OHA oral hypoglycemic agent, ARA2 angiotensin II receptor antagonist
* χ2 test
** Fisher’s exact test
n T1DM + T2DM (%) n T1DM (%) n T2DM (%) p value
Last prescription for DM
 Diet 16 1.5 0 0 16 2.1 0.00*
 OHA monotherapy 145 14.0 0 0 145 19.8
 OHA combination therapy 120 11.7 0 0 120 16.3
 Insulin + OHA combination therapy 383 37.1 38 12.7 345 47.1
 Insulin monotherapy 367 35.7 257 86.0 110 15.0
Antihyperlipidemic agents 738 71.6 132 44.1 606 82.8 0.00*
Antihypertensive agents 738 71.6 131 43.8 607 82.9 0.00**
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The proportions of T1DM and T2DM patients who 
underwent clinical and laboratory evaluations, and met 
the BDS criteria differed significantly. T1DM patients 
reached most of the goals for metabolic control (Table 5). 
However, significantly fewer T1DM patients achieved the 
targets for HbA1c than T2DM patients (p < 0.01). Signifi-
cantly more T1DM patients achieved the goals for sBP, 
dBP, HDL, and TG (p  <  0.01). Meanwhile, significantly 
more patients with T2DM achieved the goals for TC 
and LDL (p < 0.05) (Table 5). Only 0.5 % (n = 5) of the 
patients reached all targets, and 1.1  % (n =  11) did not 
reach any.
Discussion
In the present study, all outpatients received healthcare 
and treatment by an endocrinologist at a public second-
ary care service part of the NBHCS. The proportions of 
patients who achieved the targets of process measures, 
outcomes indicators, and supporting process measures 
varied substantially, and there were significant differ-
ences between T1DM and T2DM patients.
Almost no patients achieved all targets or failed to 
achieve any. Another study of T1DM patients in Brazil 
reports similar results [14]. Between 0.2 % and 7.0 % of 
patients with T2DM who had a disease duration near 
10  years achieved at least three or all targets, while 
between 8.8 and 11.4 % did not achieve any [17–19]. In 
contrast, one epidemiologic American study recent, 
large-sized, suggests that 33.4–48.7  % of persons with 
diabetes still did not meet the targets for glycemic con-
trol, blood pressure, or LDL cholesterol level and only 
14.3 % met the targets for all three of these measures and 
for tobacco use [20]. These data are different to those 
found in Brazil and indicate the need for changes in care 
plan and national policies for diabetes management.
The present results reaffirm that the achievement of 
therapeutic goals for patients with T1DM or T2DM is a 
complicated issue. Difficulty achieving appropriate gly-
cemic control, blood pressure, and lipid levels is associ-
ated with health service availability, social and economic 
factors, and education levels [17–19]. Clinical inertia and 
an inadequate support network can result in patients fail-
ing to initiate or intensify treatment in a timely manner. 
It should be noted that adherence to treatment is an issue 
with significant impact on the obtainment of goals, but 
was not assessed in our study, as the retrospective char-
acter of the collection and the absence of records of this 
parameter in the patient [21–23].
Although most patients had T2DM in the present 
study, the frequency of T1DM was relatively high, prob-
ably because the study was conducted at a secondary 
healthcare service. Patients with T1DM rarely receive 
treatment at primary care centers in Brazil [14]. How-
ever, primary care as part of the NBHCS must be assured 
to all T1DM patients [12]. T2DM patients had more vis-
its to secondary care services other than endocrinology, 
due to presence of the others comorbidities, justified by 
the older age and high BMI. As expected, T1DM patients 
made more clinical visits to an endocrinologist; this is 
because of the greater complexity of basal treatment, 
which usually requires multiple administrations of insu-
lin and the need for frequent monitoring [25–27].
As expected, patients with T2DM were significantly 
older and had significantly more chronically diseases and 
diabetes-related complications. It should be noted that 
the comparison of outcomes between T1DM and T2DM 
patients is hampered by the older age of T2DM patients 
and much longer disease duration of T1DM patients [28].
Almost half of the patients in the present study with 
T1DM were overweight. However, even more patients 
Table 5 Numbers and proportions of type 1 and 2 diabetes mellitus patients who achieved the goals for metabolic con-
trol and screening for diabetic complications
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, BMI body mass index, sBP systolic blood pressure, dBP diastolic blood pressure, TC total cholesterol, HDL 
high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, TG triglycerides
* χ2 test
T1DM + T2DM T1DM T2DM p value*
n n Goals achieved % (n) n Goals achieved % (n)
BMI 1010 299 52.5 (157) 711 14.9 (106) 0.00
sBP 1025 296 83.4 (247) 729 62.8 (458) 0.00
dBP 1025 296 88.8 (263) 729 82.0 (598) 0.00
HbA1c 1004 293 9.5 (28) 711 33.3 (237) 0.00
TC 984 287 76.3 (219) 697 81.1 (565) 0.09
HDL 986 288 55.6 (160) 698 29.7 (207) 0.00
LDL 966 281 46.2 (130) 685 58.2 (399) 0.00
TG 984 288 84.0 (242) 696 58.0 (404) 0.00
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with T2DM were overweight in accordance with the 
tendency of obesity as a global epidemic. In 2014, 39 % 
of the global adult population was overweight [29]. The 
proportions of Brazilian patients with T1DM and T2DM 
who are overweight are reported to be 29.4 and 75.4 %, 
respectively [14, 19], which are less than those in the pre-
sent study. In the United States of America, 87.7 % of out-
patients with T2DM have a BMI exceeding 25 kg/m2 [17], 
which is similar the results of the present study.
Overweight/obesity is a major risk factor for non-
communicable diseases and can lead to metabolic com-
plications [29]. Almost all patients in the present study 
were screened for metabolic control. However, exami-
nations to detect diabetes-related complications were 
rarely requested, similar to results found in other Bra-
zilian populations with T1DM and T2DM [14, 19]. Even 
though healthcare providers from community health 
centers in the United States of America consider pro-
cess measures extremely important, 25  % report for-
getting to request funduscopy and foot examinations 
[31], which is a lower proportion than that in the pre-
sent study. In an Italian study of 114,249 outpatients 
with T2DM, foot examinations were ordered for 22.4 % 
and funduscopy for 48.1  % during the preceding year, 
respectively [18]. Assessment of microalbuminuria was 
performed for 92.3 % of the patients with T2DM in the 
present study.
Eye and foot examinations were performed more fre-
quently for patients with T1DM, which may be associ-
ated with the fact that 90.5 % of T1DM patients did not 
achieve the target for HbA1c; these findings are concord-
ant with those of other studies on T1DM patients [14, 
17, 18, 33]. In a Brazilian multicenter study involving 
public secondary and tertiary clinics of the NBHCS that 
included 1800 T1DM patients (mean age 30.3 ± 9.7 years 
old), 88.4  % achieved HbA1c ≥7  % [14]. In the present 
study, 33 % of T2DM patients achieved the HbA1c target. 
The proportion of T2DM patients with similar age and 
duration of diabetes who achieved HbA1c  <7  % ranges 
between 37 and 46 % in observational studies worldwide 
[14, 17, 18, 33]. These results are worrisome and indicate 
many patients with T2DM have poor glycemic control, as 
HbA1c is the best predictor of microvascular and macro-
vascular outcomes in such patients [30, 34].
Despite glucose self-monitoring and insulin monother-
apy or insulin plus OHA combination therapy, T1DM 
patients had significantly higher HbA1c than T2DM 
patients. Adults with T2DM had HbA1c values similar 
to those in others studies involving patients with simi-
lar age and duration of diabetes (between 7.4 ± 1.5 and 
7.9 ± 1.8 %) [17, 18, 35].
Only approximately half of the total patients performed 
glucose self-monitoring. Healthcare providers report 
teaching patients to perform home glucose monitoring is 
too time consuming and that some patients cannot afford 
to do so [27]. Others reasons include a lack of appro-
priate equipment because of high costs to the NBHCS. 
Very long-term intensive glycemic control improves 
cardiovascular outcomes [14]; glucose self-monitoring 
is important considering most patients with T1DM and 
T2DM have multiple cardiovascular risk factors [14, 36] 
and that it could help achieve the goal for HBA1c.
The latest prescription for diabetes treatment differed 
between T1DM and T2DM. All patients with T1DM 
received insulin or insulin plus OHA, whereas the most 
frequent prescription for patients with T2DM was insu-
lin plus OHA therapy, which is corroborated by several 
observational studies worldwide [14, 36]. The frequen-
cies of treatment with diet alone, a single OHA, and insu-
lin monotherapy were lower in the present study than 
another Brazilian study of patients with T2DM [19].
Besides HbA1c, cardiovascular risk is related to central 
obesity, hypertension, and dyslipidemia in T1DM and 
T2DM [28, 36, 37]. However, abdominal circumference 
was not measured in most patients in the present study.
Approximately 24 and 20  % of Brazilians have hyper-
tension and dyslipidemia, respectively [12]. In the present 
study, patients with T2DM had higher blood pressure 
and TG levels, which is consistent with previous stud-
ies reporting increased risks of hypertension and dys-
lipidemia in patients with diabetes [38–41]. On the other 
hand, TC, HDL, and LDL levels were significantly higher 
in T1DM patients, whereas the number of antihyperlipi-
demic prescriptions was lower.
The present results showed 28.5 and 19.3 % of T2DM 
patients achieved the goals of sBP and dBP, respectively; 
thus, the present patients show better blood pressure 
control than those in another Brazilian study [19]. In a 
study in the United States of America, 58.9 % of T2DM 
patients showed good blood pressure control [35]. The 
median sBP in the present study is lower than the mean 
value (141  ±  19  mmHg) in Italian outpatients with 
T2DM [18]. Poor sBP and dBP are frequently observed in 
patients with T2DM [42].
As blood pressure is elevated in T2DM, the prescrip-
tions of antihypertensive agents, ACE inhibitors, and 
ARA2 were more frequent in T2DM patients than T1DM 
patients in the present study. The frequencies of pre-
scriptions of antihypertensives, ACE inhibitor, angioten-
sin receptor blockers, and aspirin in the present study 
are better than those in American and Italian studies of 
T2DM outpatients [17, 18].
In the present study, T1DM patients had significantly 
higher cholesterol fractions; 76.3 and 84.0  % of T1DM 
patients achieved the TC and TG goals, respectively, and 
44.1 % were receiving antihyperlipidemic agents.
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Patients with T2DM in the present study achieved 
the goals for TC, TG, and LDL more frequently than 
those in another Brazilian study of T2DM patients with 
similar age and duration of diabetes [19]. Studies from 
the United States of America and Italy report similar 
results: 43.7 and 29.8  % of the outpatients with T2DM 
had LDL  <100  mg/dL, respectively [17, 18]. However, 
in a recent American study, 62.8  % of T2DM patients 
achieved the target for LDL [35]. In the present study, 
fewer patients with T1DM were prescribed antihyperlipi-
demic agents than T2DM patients. These results are bet-
ter than those reported in the United States of America 
(58.8 %) [17].
The greater proportions of antihyperlipidemic, anti-
hypertensive, and aspirin prescriptions as well as the 
frequent insulin recommendation for T2DM treatment 
suggest a change in clinical inertia and earlier treatment 
intensification. However, these results do not directly 
demonstrate the adequacy of a support network with 
multidisciplinary diabetes care teams focusing on dia-
betes self-management education as well as social, eco-
nomic, and environmental improvements in order to 
increase treatment adherence (mainly physical activity 
and diet recommendations).
The present results show nutritional and physical edu-
cation activities are frequently omitted from most medi-
cal records. Nutritional education was recorded in less 
than half of the total patients’ records; it was most fre-
quently recorded for T2DM patients and was probably 
prescribed by physicians, because only 2  % of patients 
had a nutritional consultation recorded in their medical 
records.
The present results suggest physicians do not appro-
priately refer patients to dietitians, probably because of 
the lack of dieticians in the healthcare system or because 
physicians considered their dietary recommendations 
sufficient. Providers state patients are unable to follow a 
diet or exercise program regularly but consider special 
diets and exercise very or extremely important processes; 
therefore, dietitians are one of the most common health 
professionals to whom primary care clinicians refer their 
patients [17, 31]. A regular and balanced diet in conjunc-
tion with pharmacotherapy is fundamental for the treat-
ment of diabetes [34, 43, 44].
Moreover, smoking cessation was often neglected by 
physicians according to the medical records. Smok-
ing status was registered in few medical records, indi-
cating an assumption of a reduced number of smokers. 
The proportion of T2DM patients whose smoking status 
was recorded in the present study is lower than that in a 
multicenter study in Brazil (54.5 %) [19]. Meanwhile, the 
frequency of current smoking status in T1DM patients 
is similar to that in another Brazilian multicenter (7.3 %) 
[14].
Trained care physicians and multidisciplinary diabetes 
care teams can aid diabetes self-management education, 
blood pressure control, lipid profile, early improvement 
intensive glycemic control, insulin and hypoglycemic 
agent dose adjustments, and hyperglycemia treatment, all 
of which slow the progression of chronic complications 
and improve quality of life [28, 41–43].
Social and environmental burdens are the main rea-
sons for necessary lifestyle modifications in the manage-
ment of diabetes. Nonadherence to self-care behaviors is 
common among patients with diabetes and is often asso-
ciated with a poor understanding of the disease and its 
treatment [24].
The management of outpatients with T1DM and 
T2DM, including improving metabolic control and 
reducing the risk of developing diabetes-related com-
plications, is challenging for healthcare systems. A large 
integrated and redesigned healthcare system with more 
healthcare professionals and trained multidisciplinary 
teams, patient education programs, prioritized public 
policies on non-communicable diseases, and improved 
structural and financial access to care are necessary to 
promote appropriate interventions to spur behavioral 
changes in such patients [31, 32].
Patient satisfaction with diabetes care is a component 
of quality measurement, but was not found in any medi-
cal record in the present study. The quality of diabetes 
care, which includes process and intermediate outcome 
indicators, must be addressed more carefully in order to 
promote continuous improvement initiatives and develop 
a more effective healthcare model for these patients [14, 
18, 19].
A limitation of the study is that it was conducted in 
a single service, so the generalization of data should be 
performed with caution. However, this limitation may 
have been softened, due to high sample number and the 
wide variability of patients assessed, considering that the 
service in question is an important reference center for 
the whole region.
Conclusion
The proportions of patients with T1DM and T2DM who 
achieve the goals of good clinical practice during rou-
tine secondary endocrine care in the NBHCS Support 
Network vary with respect to the parameters evaluated. 
Almost no patients achieved all targets. Many patients 
are overweight and have not achieved the targets for 
HbA1c, lipid profile, or blood pressure control. Further-
more, nutrition, physical activity, and smoking cessation 
education activities are neglected in medical records, and 
Page 8 of 9Baptista et al. Diabetol Metab Syndr  (2015) 7:113 
examinations for detecting diabetes complications are 
not sufficiently requested.
There are limitations when comparing patients with 
T1DM and T2DM because of the differences in the dis-
ease characteristics; nevertheless, the therapeutic targets 
are the same for both diseases. Moreover, the achieve-
ment of goals is indicative of the healthcare quality of 
the Support Network, suggesting care practice must be 
reviewed to improve the metabolic control of patients 
with diabetes. Therefore, further prospective studies 
investigating healthcare quality through the assessment 
of care for chronic conditions by using direct question-
naires and measurement indexes are warranted.
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